Clinical trials: Hair Problems
Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA).
- Trial name
- NCT07311564
- Testing
- LAD603
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Almirall, S.A.
Female Pattern Hair Loss, Androgenetic Alopecia (AGA)
A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss
Pantovigar - a high effective product designed primarily for the treatment of diffuse hair loss in women as well as for the treatment of damaged hair, in the combined therapy can be successfully applied in other types of…
- Conditions
- Female Pattern Hair Loss, Androgenetic Alopecia (AGA), Ludwig Type 1, Ludwig Type 2
- Trial name
- NCT01900041
- Testing
- Pantovigar, Minoxidil 2% only
- Where
- 2 sites in Russia
- Volunteers
- 74 people
- Sponsor
- Merz Pharmaceuticals GmbH
Androgenetic Alopecia, Androgenic Alopecia
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
To demonstrate that the ALRV5XR multi-molecular targeting treatment regimen of a daily shampoo, conditioner, topical serum and oral supplement is superior to placebo in promoting hair growth as assessed by change in hair density…
- Conditions
- Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair
- Trial name
- REBOOT-MEN (NCT04450589)
- Testing
- ALRV5XR, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Arbor Life Labs
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Neoplasms, Alopecia
START: Swiss Taxotere Alopecia Prevention Trial
Primary objective: Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading) Secondary objective: Compliance to scalp cooling procedure Received number of cycles of chemotherapy in each subgroup…
- Trial name
- NCT01008774
- Testing
- Paxman Cooling Machine, Cold Caps
- Where
- Switzerland
- Volunteers
- 239 people
- Sponsor
- Sanofi
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451099
- Testing
- Autologous cultured dermal cells
- Where
- 6 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
To Evaluate the Pharmacokinetics and Safety of AD-208
To evaluate pharmacokinetics and safety of AD-208.
- Trial name
- NCT04214808
- Testing
- AD-208, Avodart Soft Capsule 0.5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hair Thinning
Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men
A single-center, open-label, prospective study to demonstrate the efficacy of an oral supplement to improve the strength and support the growth of thinning hair in men and women with self-perceived hair thinning.
- Trial name
- NCT06362941
- Testing
- Nutrafol Women's Hair Growth Supplemnt, Nutrafol Women's Balance Hair Growth Supplement, Nutrafol Women's Vegan Hair Growth Supplement
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Nutraceutical Wellness Inc.
Prevention of Chemotherapy-induced Myelosuppression
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with…
- Trial name
- NCT05622058
- Testing
- ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
- Where
- 14 sites in United States, Bosnia and Herzegovina and 2 more
- Volunteers
- 6 people
- Sponsor
- Aileron Therapeutics, Inc.
Male Pattern Baldness, Androgenetic Alopecia
Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss
The purpose of this 24-week study is to see if the SAGA-001 device is safe and effective at helping people with male pattern hair loss. Two different device configurations are being explored as part of this study.
- Conditions
- Male Pattern Baldness, Androgenetic Alopecia, Hair Loss/Baldness, Hair Loss
- Trial name
- CS-SAGA-001 (NCT05970809)
- Testing
- SAGA-001 (A), SAGA-001 (B)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 82 people
- Sponsor
- StimuSIL
Hypotrichosis
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in…
- Trial name
- NCT00958035
- Testing
- bimatoprost ophthalmic 0.03% solution
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Allergan
Alopecia
Hairstetics Hair Implant Device Safety and Efficacy
This is a prospective, single-arm, multi-center, international, open-label, non-randomized, clinical study. The aim of the study is to assess the safety and efficacy of the use of the Hairstetics hair implant device in subjects…
- Trial name
- NCT02856308
- Testing
- Hairstetics hair implant device
- Where
- 8 sites in France, India and 2 more
- Volunteers
- 100 people
- Sponsor
- Hairstetics
Alopecia, Female Pattern Hair Loss
Minoxidil Response Testing in Females With Female Pattern Hair Loss
The primary purpose of this study is to evaluate the clinical validity of the minoxidil response in-vitro diagnostic kit.
- Trial name
- NCT02206802
- Testing
- 5% minoxidil topical foam
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia, Androgenic Alopecia
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
To demonstrate that the ALRV5XR multi-molecular targeting treatment regimen of a daily shampoo, conditioner, topical serum and oral supplement is superior to placebo in promoting hair growth as assessed by change in hair density…
- Conditions
- Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair
- Trial name
- REBOOT-WOMEN (NCT04450602)
- Testing
- ALRV5XR, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Arbor Life Labs
Androgenetic Alopecia, AGA
Safety and Efficacy of VDPHL01 in Males and Females With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06527365
- Testing
- VDPHL01
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Veradermics, Inc.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Alopecia Areata
A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects
This is a First-in-Human phase I study to evaluate the safety, tolerability and pharmacokinetic characteristics of MAX-40070 in Healthy SubjectThe study will be comprised of 2 parts; Part A and Part B.
- Trial name
- NCT05196711
- Testing
- MAX-40070
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Maxinovel Pty., Ltd.
Alopecia Areata
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03137381
- Testing
- CTP-543
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Concert Pharmaceuticals